Howe & Rusling’s Beam Therapeutics BEAM Stock Holding History

Howe & Rusling’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25	Closed	-$1K	–	1060
2022 Q2	$1K	Buy	+25	New	+$994	﹤0.01%	927

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Howe & Rusling's BEAM Position: Q3 2022 in Review

Howe & Rusling sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 25 shares — an estimated $1K sold.

Howe & Rusling first reported a position in BEAM in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

Howe & Rusling reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 25 Beam Therapeutics shares in Q3 2022, an estimated $1K.
Howe & Rusling first reported a position in Beam Therapeutics in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Beam Therapeutics position peaked at $1K in Q2 2022.
224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.